Global ADHD Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 152690
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 124
  • list Pharmaceuticals and Healthcare

Attention Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder with an estimated global prevalence of 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in the adult population has risen in the past decade. However, diagnosis remains difficult due to unknown genetic causes and a lack of accurate biomarkers.

Scope of the Report:

The worldwide market for ADHD Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

This report focuses on the ADHD Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

Eli Lilly

Novartis

Shire

Pfizer

GlaxoSmithKline

Mallinckrodt Pharmaceuticals

Hisamitsu Pharmaceutical

Impax Laboratories

Johnson & Johnson

UCB S.A.

Purdue Parma

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Stimulants

Non-stimulants

Market Segment by Applications, can be divided into

Specialty Clinics

Hospital Pharmacies

Retail Pharmacies

E-Commerce

There are 15 Chapters to deeply display the global ADHD Therapeutics market.

Chapter 1, to describe ADHD Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of ADHD Therapeutics, with sales, revenue, and price of ADHD Therapeutics, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of ADHD Therapeutics, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, ADHD Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe ADHD Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 ADHD Therapeutics Introduction

1.2 Market Analysis by Type

1.2.1 Stimulants

1.2.2 Non-stimulants

1.3 Market Analysis by Applications

1.3.1 Specialty Clinics

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 E-Commerce

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Eli Lilly

2.1.1 Business Overview

2.1.2 ADHD Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Eli Lilly ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Novartis

2.2.1 Business Overview

2.2.2 ADHD Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Novartis ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Shire

2.3.1 Business Overview

2.3.2 ADHD Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Shire ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Pfizer

2.4.1 Business Overview

2.4.2 ADHD Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Pfizer ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 GlaxoSmithKline

2.5.1 Business Overview

2.5.2 ADHD Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 GlaxoSmithKline ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Mallinckrodt Pharmaceuticals

2.6.1 Business Overview

2.6.2 ADHD Therapeutics Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Mallinckrodt Pharmaceuticals ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Hisamitsu Pharmaceutical

2.7.1 Business Overview

2.7.2 ADHD Therapeutics Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Hisamitsu Pharmaceutical ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 Impax Laboratories

2.8.1 Business Overview

2.8.2 ADHD Therapeutics Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Impax Laboratories ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9 Johnson & Johnson

2.9.1 Business Overview

2.9.2 ADHD Therapeutics Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Johnson & Johnson ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10 UCB S.A.

2.10.1 Business Overview

2.10.2 ADHD Therapeutics Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 UCB S.A. ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.11 Purdue Parma

2.11.1 Business Overview

2.11.2 ADHD Therapeutics Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Purdue Parma ADHD Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global ADHD Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global ADHD Therapeutics Sales and Market Share by Manufacturer (2016-2017)

3.2 Global ADHD Therapeutics Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 ADHD Therapeutics Manufacturer Market Share in 2017

3.3.2 Top 6 ADHD Therapeutics Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global ADHD Therapeutics Market Analysis by Regions

4.1 Global ADHD Therapeutics Sales, Revenue and Market Share by Regions

4.1.1 Global ADHD Therapeutics Sales and Market Share by Regions (2013-2018)

4.1.2 Global ADHD Therapeutics Revenue and Market Share by Regions (2013-2018)

4.2 North America ADHD Therapeutics Sales and Growth Rate (2013-2018)

4.3 Europe ADHD Therapeutics Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific ADHD Therapeutics Sales and Growth Rate (2013-2018)

4.5 South America ADHD Therapeutics Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa ADHD Therapeutics Sales and Growth Rate (2013-2018)

5 North America ADHD Therapeutics by Countries

5.1 North America ADHD Therapeutics Sales, Revenue and Market Share by Countries

5.1.1 North America ADHD Therapeutics Sales and Market Share by Countries (2013-2018)

5.1.2 North America ADHD Therapeutics Revenue and Market Share by Countries (2013-2018)

5.2 United States ADHD Therapeutics Sales and Growth Rate (2013-2018)

5.3 Canada ADHD Therapeutics Sales and Growth Rate (2013-2018)

5.4 Mexico ADHD Therapeutics Sales and Growth Rate (2013-2018)

6 Europe ADHD Therapeutics by Countries

6.1 Europe ADHD Therapeutics Sales, Revenue and Market Share by Countries

6.1.1 Europe ADHD Therapeutics Sales and Market Share by Countries (2013-2018)

6.1.2 Europe ADHD Therapeutics Revenue and Market Share by Countries (2013-2018)

6.2 Germany ADHD Therapeutics Sales and Growth Rate (2013-2018)

6.3 UK ADHD Therapeutics Sales and Growth Rate (2013-2018)

6.4 France ADHD Therapeutics Sales and Growth Rate (2013-2018)

6.5 Russia ADHD Therapeutics Sales and Growth Rate (2013-2018)

6.6 Italy ADHD Therapeutics Sales and Growth Rate (2013-2018)

7 Asia-Pacific ADHD Therapeutics by Countries

7.1 Asia-Pacific ADHD Therapeutics Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific ADHD Therapeutics Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific ADHD Therapeutics Revenue and Market Share by Countries (2013-2018)

7.2 China ADHD Therapeutics Sales and Growth Rate (2013-2018)

7.3 Japan ADHD Therapeutics Sales and Growth Rate (2013-2018)

7.4 Korea ADHD Therapeutics Sales and Growth Rate (2013-2018)

7.5 India ADHD Therapeutics Sales and Growth Rate (2013-2018)

7.6 Southeast Asia ADHD Therapeutics Sales and Growth Rate (2013-2018)

8 South America ADHD Therapeutics by Countries

8.1 South America ADHD Therapeutics Sales, Revenue and Market Share by Countries

8.1.1 South America ADHD Therapeutics Sales and Market Share by Countries (2013-2018)

8.1.2 South America ADHD Therapeutics Revenue and Market Share by Countries (2013-2018)

8.2 Brazil ADHD Therapeutics Sales and Growth Rate (2013-2018)

8.3 Argentina ADHD Therapeutics Sales and Growth Rate (2013-2018)

8.4 Colombia ADHD Therapeutics Sales and Growth Rate (2013-2018)

9 Middle East and Africa ADHD Therapeutics by Countries

9.1 Middle East and Africa ADHD Therapeutics Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa ADHD Therapeutics Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa ADHD Therapeutics Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia ADHD Therapeutics Sales and Growth Rate (2013-2018)

9.3 UAE ADHD Therapeutics Sales and Growth Rate (2013-2018)

9.4 Egypt ADHD Therapeutics Sales and Growth Rate (2013-2018)

9.5 Nigeria ADHD Therapeutics Sales and Growth Rate (2013-2018)

9.6 South Africa ADHD Therapeutics Sales and Growth Rate (2013-2018)

10 Global ADHD Therapeutics Market Segment by Type

10.1 Global ADHD Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global ADHD Therapeutics Sales and Market Share by Type (2013-2018)

10.1.2 Global ADHD Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Stimulants Sales Growth and Price

10.2.1 Global Stimulants Sales Growth (2013-2018)

10.2.2 Global Stimulants Price (2013-2018)

10.3 Non-stimulants Sales Growth and Price

10.3.1 Global Non-stimulants Sales Growth (2013-2018)

10.3.2 Global Non-stimulants Price (2013-2018)

11 Global ADHD Therapeutics Market Segment by Application

11.1 Global ADHD Therapeutics Sales Market Share by Application (2013-2018)

11.2 Specialty Clinics Sales Growth (2013-2018)

11.3 Hospital Pharmacies Sales Growth (2013-2018)

11.4 Retail Pharmacies Sales Growth (2013-2018)

11.5 E-Commerce Sales Growth (2013-2018)

12 ADHD Therapeutics Market Forecast (2018-2023)

12.1 Global ADHD Therapeutics Sales, Revenue and Growth Rate (2018-2023)

12.2 ADHD Therapeutics Market Forecast by Regions (2018-2023)

12.2.1 North America ADHD Therapeutics Market Forecast (2018-2023)

12.2.2 Europe ADHD Therapeutics Market Forecast (2018-2023)

12.2.3 Asia-Pacific ADHD Therapeutics Market Forecast (2018-2023)

12.2.4 South America ADHD Therapeutics Market Forecast (2018-2023)

12.2.5 Middle East and Africa ADHD Therapeutics Market Forecast (2018-2023)

12.3 ADHD Therapeutics Market Forecast by Type (2018-2023)

12.3.1 Global ADHD Therapeutics Sales Forecast by Type (2018-2023)

12.3.2 Global ADHD Therapeutics Market Share Forecast by Type (2018-2023)

12.4 ADHD Therapeutics Market Forecast by Application (2018-2023)

12.4.1 Global ADHD Therapeutics Sales Forecast by Application (2018-2023)

12.4.2 Global ADHD Therapeutics Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure ADHD Therapeutics Picture

Table Product Specifications of ADHD Therapeutics

Figure Global Sales Market Share of ADHD Therapeutics by Types in 2017

Table

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery